ID
40953
Beschrijving
The primary focus of this first time in human (FTIH) study was to evaluate the safety and tolerability of GSK1292263 and to estimate GSK1292263 pharmacokinetic (PK) parameters and pharmacodynamic (PD) effects in healthy volunteers. Subject: FTIH, oral, safety, tolerability, pharmacokinetics, glucose, pharmacodynamics, male, female, gastric emptying Indication Studied: Type 2 Diabetes Mellitus Study ID: 111596 Clinical Study ID: 111596 Study Title: A study in healthy volunteers of single doses of orally administered GSK1292263 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound alone and when co-administered with sitagliptin Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00783549 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK1292263, Sitagliptin Trade Name: N/A Study Indication: Dyslipidaemias
Trefwoorden
Versies (2)
- 25-04-20 25-04-20 -
- 07-06-20 07-06-20 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
7 juni 2020
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
A study in healthy volunteers of single doses of orally administered GSK1292263 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound alone and when co-administered with sitagliptin
Medical conditions (Liver MEDHX), Liver Event 5-DF
- StudyEvent: ODM
Beschrijving
Drug related liver disease conditions (All drugs including Investigational Product)
Alias
- UMLS CUI-1
- C0023895
- UMLS CUI-2
- C0277579
Beschrijving
Other liver disease conditions
Beschrijving
[hidden] Item is not required
Datatype
text
Alias
- UMLS CUI [1]
- C2348184
Beschrijving
Specific Condition
Datatype
text
Alias
- UMLS CUI [1,1]
- C0012634
- UMLS CUI [1,2]
- C2348235
Beschrijving
[hidden] Item is not required
Datatype
text
Alias
- UMLS CUI [1]
- C2826302
Beschrijving
[hidden]
Datatype
text
Alias
- UMLS CUI [1]
- C1140263
Beschrijving
[hidden]
Datatype
text
Alias
- UMLS CUI [1]
- C2347090
Beschrijving
[hidden]
Datatype
text
Alias
- UMLS CUI [1,1]
- C0805701
- UMLS CUI [1,2]
- C0231175
Beschrijving
Status
Datatype
integer
Alias
- UMLS CUI [1]
- C0449438
Beschrijving
Other medical conditions
Beschrijving
Drug Allergies
Datatype
integer
Alias
- UMLS CUI [1]
- C0013182
Beschrijving
Rheumatoid Arthritis
Datatype
integer
Alias
- UMLS CUI [1]
- C0003873
Beschrijving
Psoriasis
Datatype
integer
Alias
- UMLS CUI [1]
- C0033860
Beschrijving
Thyroid Disease
Datatype
integer
Alias
- UMLS CUI [1]
- C0040128
Beschrijving
Inflammatory Bowel Disease
Datatype
integer
Alias
- UMLS CUI [1]
- C0021390
Beschrijving
Lupus
Datatype
integer
Alias
- UMLS CUI [1]
- C0409974
Beschrijving
Sjogren's Syndrome
Datatype
integer
Alias
- UMLS CUI [1]
- C1527336
Beschrijving
Vitiligo
Datatype
integer
Alias
- UMLS CUI [1]
- C0042900
Similar models
Medical conditions (Liver MEDHX), Liver Event 5-DF
- StudyEvent: ODM
C0262926 (UMLS CUI-2)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
C0014644 (UMLS CUI [1,2])
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
C3275124 (UMLS CUI [2])
(Comment:en)
(Comment:en)
(Comment:en)
C0277579 (UMLS CUI-2)
C0277579 (UMLS CUI [1,2])
(Comment:en)
(Comment:en)
(Comment:en)
C2348235 (UMLS CUI [1,2])
C0231175 (UMLS CUI [1,2])
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)